A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Inclusion Criteria:

• Adults (from at least 18 years of age) with AD as defined by the American Academy ofDermatology Consensus Criteria for 1 year or longer prior to screening.

• AD disease severity at screening and randomization:

• EASI of 16 or higher

• IGA of 3 or 4

• BSA of 10% or more

• Documented history, within 6 months prior to the screening visit, of eitherinadequate response or inadvisability of topical treatments.

• Able to complete patient questionnaires.

• Able and willing to comply with requested study visits and procedures.

• Able and willing to provide written informed consent.

Exclusion Criteria:

• Prior use of systemic immune modulating therapies for AD (i.e., JAK inhibitors orbiologics)

• Other skin conditions that would interfere with assessment of AD

• Treatment with a live (attenuated) immunization within 12 weeks prior to screening.

• Men and women (of reproductive potential) unwilling to use highly effective birthcontrol and women who are pregnant or breastfeeding.

• Any malignancies or history of malignancies within 5 years prior to randomization (except for basal cell or squamous epithelial carcinomas of the skin that have beensuccessfully treated with no evidence of metastatic disease for 3 years or cervicalcarcinoma in situ that has been successfully treated, with no evidence of recurrencewithin the 3 years prior to randomization).

• Known history of, or suspected, significant current immunosuppression, includinghistory of invasive opportunistic infections despite infection resolution orotherwise recurrent infections of abnormal frequency or prolonged duration.

• Positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV) orhepatitis C virus (HCV) at screening.

• Severe concomitant illness that would in the Investigator's opinion inhibit thepatient's participation in the study, including for example, but not limited to,hypertension, renal disease, neurological conditions, heart failure and pulmonarydisease.

• Concurrent participation in any other investigational clinical study.